# Evolution Bio **Type:** venture **Status:** Draft **Confidence:** Low **Focus:** directed evolution, GPCR engineering, protein engineering, drug-discovery platform, mammalian cell screening **Stage:** Early; Nucleus Fund, University of Utah, and Altitude Lab backing (circa 2022) **Location:** Salt Lake City, UT **Updated:** 2026-06-19 **Needs-reviewed:** 2026-06-19 **Hero:** https://picsum.photos/seed/evolution-bio-vegas-gpcr-platform-2026/1600/1100 **Pull:** *Mammalian directed evolution for GPCRs — the drug industry's hardest, highest-value target class.* **Relates:** cites [English Lab (University of Utah)](evolution-bio-english-lab.md), [VEGAS as a Platform for Facile Directed Evolution in Mammalian Cells](evolution-bio-vegas-cell-paper.md) ## Summary Evolution Bio is a Salt Lake City biotechnology company, founded circa 2022, built around directed protein evolution for drug discovery — especially G-protein coupled receptors (GPCRs). The venture appears to spin out of University of Utah biochemistry research by Dr. Justin English, who invented the VEGAS (Viral Evolution of Genetically Actuated Sequences) mammalian directed-evolution platform published in *Cell* (2019). Public investor listings name the Nucleus Fund, University of Utah, and Altitude Lab as backers. Altitude Lab describes the company as using a novel drug-discovery platform to optimize biological therapeutic candidates. **No standalone company website was confirmed during this migration** — intake relied on the English Lab site, the VEGAS publication, Altitude Lab portfolio metadata, and third-party directories. ## Impact GPCRs are among the most important target classes in pharmacology — roughly one-third of FDA-approved drugs act on GPCRs — yet they remain difficult to engineer and screen in formats that reflect human cell pharmacology. Traditional directed evolution in bacteria or yeast often produces variants that behave differently in mammalian systems. VEGAS performs selection in mammalian cells using Sindbis virus as a vector for heredity and diversification, with reported 24-hour selection cycles and week-scale campaigns for transcription factors, GPCRs, and nanobodies. If a commercial platform reliably delivers mammalian-evolved GPCR variants, it could shorten pharma discovery cycles for an enormous target class. That commercial promise remains early and partially contested in the literature (see Open Questions). ## What They Are Building Evolution Bio's model, inferred from lab and portfolio descriptions, is **platform infrastructure** rather than a traditional single-asset drug company: license or contract VEGAS-based protein engineering to pharma and biotech partners, or apply the platform internally to optimize therapeutic candidates across target classes. The English Lab continues active VEGAS expansion work — new selection paradigms, nanobody libraries for GPCR control, and GPCR pharmacogenomics — which may feed the company's technology base. The relationship between ongoing academic lab work and corporate IP boundaries is not documented on the pages captured here. ## What They Need Now Likely needs include protein engineers and molecular biologists experienced in mammalian cell culture and viral systems, GPCR pharmacology specialists, synthetic-biology engineers, pharma business-development leaders, and patent counsel for platform licensing. Early-stage platform companies also need reference customers or partnership announcements that validate repeatability beyond the original *Cell* demonstrations. ## Who Could Help Useful helpers include GPCR structural biology advisors, pharma discovery executives with platform-tool procurement experience, viral-vector biosafety consultants, and investors who understand tool-company economics versus therapeutic multiples. [Altitude Labs](altitude-labs.md) infrastructure may be relevant given Altitude Lab's listed investment. ## Utah Context Evolution Bio is a University of Utah biochemistry spinout in Salt Lake City, backed by Utah's Nucleus Fund and resident in the Altitude Lab ecosystem (Recursion-affiliated incubator). It connects Utah's academic GPCR pharmacology depth — English Lab, Roth-lab lineage in the VEGAS paper — to the Wasatch Front's growing platform-biotech cluster. ## Evidence - [English Lab (University of Utah)](evolution-bio-english-lab.md) - [VEGAS as a Platform for Facile Directed Evolution in Mammalian Cells](evolution-bio-vegas-cell-paper.md) ## See Also - [Intactis Bio](intactis-bio.md) — another early Altitude Lab–associated Utah deep-tech spinout - [Altitude Labs](altitude-labs.md) — Utah health-care incubator listed as an investor ## Open Questions - **Company website unknown.** BioUtah lists Evolution Bio with a "Visit Website" link that did not resolve to a confirmed URL during intake. A site at discovery-evolution.com describes a "digital directed evolution" GPCR antibody platform and may represent a rebrand, separate entity, or successor — relationship to Evolution Bio is unverified. - **Pharma partnerships unverified.** Prior intake mentioned Eli Lilly and Kallyope partnerships; no primary source confirming those deals was captured in this migration. Treat as unverified until press release or SEC filing appears. - **VEGAS technical limitations.** Independent reviews have questioned continuous Sindbis-based evolution (packaging competition, cheater emergence, biosafety of alphavirus vectors). These concerns affect how strongly to claim VEGAS as a production-ready commercial platform. - **Corporate vs. academic boundary.** How much VEGAS IP and ongoing development sit in Evolution Bio versus the English Lab is unclear without cap-table, licensing, or company filings. - **Funding amount and valuation** beyond investor names (PitchBook, Altitude Lab) are not public in sources reviewed. - **Dedicated source pages** for Altitude Lab portfolio entry, PitchBook profile, and BioUtah listing would improve evidence coverage. - The placeholder hero should be replaced with a cleared lab or platform image when rights are confirmed.